LONDON — Biomarker pioneer Inoviv has secured significant funding from venture capital firm Hoxton Ventures and leading investment manager Foresight Group to expand the delivery of highly accurate, fully quantitative targeted biomarker workflows and panels. Building on previous funding from Hoxton Ventures, this latest investment will enable Inoviv to further expand its commercial activities to […]
Funding will accelerate commercialization of the Singulator platform which enables single cell or nuclei suspensions from solid tissues LIVERMORE, Calif. — S2 Genomics, the leading manufacturer of tissue sample preparation systems for single cell genomics assays, announced today that it has raised $16 million in Series A funding from BroadOak Capital Partners and Research Corporation […]
CellVoyant, an AI-first biotechnology spin-out from the University of Bristol accelerating the development of new stem cell therapies, has announced a £7.6 million seed round. The company aims to enable the cost-effective, reliable, and rapid development of new cell therapies. Stem cells unlock a range of treatment possibilities that have not previously been available to […]
SEATTLE — Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major fundraising round led by BroadOak Capital Partners. The oversubscribed funding round also featured participation from existing investors and key opinion leaders across the life sciences industry. This infusion of capital […]
SANTA CLARA, Calif. — Agilent Technologies Inc. (NYSE: A) today announced it has moved the company’s Cell Analysis Division into its Diagnostics and Genomics Group (DGG) as part of a strategy to further strengthen growth opportunities for both organizations. “We believe having the cell analysis team as part of DGG is a natural fit given […]
MicrofluidX secures £1m funding via Innovate UK Investor Partnerships Future Economy programme, supported by Longwall Ventures. Stevenage, UK– MicrofluidX (MFX), a UK-based developer of technologies that streamline the development and deployment of cell and gene therapies, is delighted to announce that it has been awarded £685,000 in funding from Innovate UK via their Investor Partnership […]
Funding will drive expansion of company’s product portfolio and commercial reach. SEATTLE — Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has closed a total of $50 million in financing from a Series C equity raise and the closing of a debt facility. Soleus Capital led the Series […]
Technology, in-licensed from the Massachusetts Institute of Technology (MIT), capable of inserting DNA sequences of any size into any programmed genomic location Potential to create curative cell and integrative gene therapies Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others Watertown, MA – Tome Biosciences, Inc., the programmable genomic integration company, has […]
Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024 MaxCyte is reiterating 2023 expected core business revenue of $28-30 million, and the Company now expects to […]
WOBURN, Mass. — Spear Bio Inc., a Harvard University biotech spin-off developing scalable solutions for ultrasensitive detection of protein biomarkers, announced the completion of a raise of tens of millions of US dollars with its Seed Prime. The oversubscribed round was led by CDH Investments, with additional investments from earlier investors such as Maverick Ventures and YongHua […]
Pay Invoice
Latest Blogs
-
MOBILion Expands into Proteomics MS Market
April 30, 2026 5:05 pm
-
Carterra Introduces Faster SPR
March 27, 2026 7:26 pm
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
